Table 3 Baseline characteristics according to CKD stage in Patients with CKD
From: Prevalence and incidence of chronic kidney disease stage 3–5 – results from KidDiCo
Total | CKD 3a | CKD 3b | CKD 4 | CKD 5 | ESKD | p-value | ||
|---|---|---|---|---|---|---|---|---|
N = 66,486 | N = 44,620 | N = 15,765 | N = 4359 | N = 1176 | N = 566 | |||
Sex | male | 26,305 (39.6%) | 17,267 (38.7%) | 6156 (39.0%) | 1893 (43.4%) | 657 (55.9%) | 332 (58.7%) | < 0.001 |
female | 40,181 (60.4%) | 27,353 (61.3%) | 9609 (61.0%) | 2466 (56.6%) | 519 (44.1%) | 234 (41.3%) | ||
Age mean | 76.4 (69–83) | 75 (68–81.4) | 80 (73–85.6) | 81 (72.4–87) | 73.64999 (62.85–82.9) | 62 (47–73) | < 0.001 | |
Age group (in years) | 18–29 | 137 (0.2%) | 42 (0.1%) | 26 (0.2%) | 15 (0.3%) | 17 (1.4%) | 37 (6.5%) | < 0.001 |
30–39 | 322 (0.5%) | 119 (0.3%) | 80 (0.5%) | 46 (1.1%) | 34 (2.9%) | 43 (7.6%) | ||
40–49 | 936 (1.4%) | 553 (1.2%) | 149 (0.9%) | 82 (1.9%) | 76 (6.5%) | 76 (13.4%) | ||
50–59 | 3564 (5.4%) | 2600 (5.8%) | 571 (3.6%) | 172 (3.9%) | 123 (10.5%) | 98 (17.3%) | ||
60–69 | 13,193 (19.8%) | 10,267 (23.0%) | 2027 (12.9%) | 534 (12.3%) | 237 (20.2%) | 128 (22.6%) | ||
70–79 | 23,507 (35.4%) | 17,035 (38.2%) | 4909 (31.1%) | 1135 (26.0%) | 298 (25.3%) | 130 (23.0%) | ||
80 and over | 24,827 (37.3%) | 14,004 (31.4%) | 8003 (50.8%) | 2375 (54.5%) | 391 (33.2%) | 54 (9.5%) | ||
Diabetes | no | 55,080 (82.8%) | 37,464 (84.0%) | 12,848 (81.5%) | 3429 (78.7%) | 930 (79.1%) | 409 (72.3%) | < 0.001 |
yes | 11,406 (17.2%) | 7156 (16.0%) | 2917 (18.5%) | 930 (21.3%) | 246 (20.9%) | 157 (27.7%) | ||
Hypertension | no | 12,741 (19.2%) | 9872 (22.1%) | 2108 (13.4%) | 528 (12.1%) | 201 (17.1%) | 32 (5.7%) | < 0.001 |
yes | 53,745 (80.8%) | 34,748 (77.9%) | 13,657 (86.6%) | 3831 (87.9%) | 975 (82.9%) | 534 (94.3%) | ||
Cardiovascular diseases | no | 47,177 (71.0%) | 33,424 (74.9%) | 10,077 (63.9%) | 2527 (58.0%) | 763 (64.9%) | 386 (68.2%) | < 0.001 |
yes | 19,309 (29.0%) | 11,196 (25.1%) | 5688 (36.1%) | 1832 (42.0%) | 413 (35.1%) | 180 (31.8%) | ||
Albuminuria stage | A1 | 4942 (79.7%) | 3667 (82.6%) | 1028 (76.0%) | 191 (62.4%) | 22 (43.1%) | 34 (66.7%) | < 0.001 |
A2 | 1090 (17.6%) | 687 (15.5%) | 282 (20.9%) | 93 (30.4%) | 15 (29.4%) | 13 (25.5%) | ||
A3 | 168 (2.7%) | 86 (1.9%) | 42 (3.1%) | 22 (7.2%) | 14 (27.5%) | 4 (7.8%) | ||
Albumin assesment rate | assessed | 6200 (9.3%) | 4440 (10.0%) | 1352 (8.6%) | 306 (7.0%) | 51 (4.3%) | 51 (9.0%) | < 0.001 |
not assessed | 60,286 (90.7%) | 40,180 (90.0%) | 14,413 (91.4%) | 4053 (93.0%) | 1125 (95.7%) | 515 (91.0%) |